Search Follow us

heidelberg

1 - 12 of 35
Sort by: popularity | newest
Page  2 3  of 3 | Next
Heidelberg Pharma

Executive Interview - Heidelberg Pharma

Edison TV: | Pharmaceutical & healthcare | 06 Dec 2018

Dr Jan Schmidt-Brand, CEO and CFO of Heidelberg discusses the group’s core technology and applications. In particular, he focuses on Heidelberg's lead product HDP-101’s route to market and its advantages over the current standard of care and competitors such as CAR-T and ADCs.

Heidelberg Pharma

Close to ATAC

QuickView | Pharmaceutical & healthcare | 19 Nov 2018

Heidelberg Pharma's strategy is twofold: to develop a proprietary pipeline of Antibody Targeted Amanitin Conjugates and sign early research and option deals with pharmaceutical companies to develop targets using the ATAC platform. Heidelberg should file an IND for its proprietary product, HDP-101, for multiple myeloma in Q219. The company has signed a deal with Magenta Pharmaceuticals potentially worth up to $334m and has a deal with Takeda that could yield up to $83.5m per target. Cash at Q318 was €22.7m, which Heidelberg expects to last into 2020.

Heidelberg Pharma

ATACking cancer cells with novel technology

QuickView | Pharmaceutical & healthcare | 16 Nov 2017

Heidelberg Pharma is building a proprietary pipeline of Antibody Targeted Amanitin Conjugates (ATACs). Lead product, HDP-101, is in preparation to start clinical development at the end of 2018. The company has a back-loaded research and option deal with Takeda that could be worth up to $113m per product. The investment case rests on its current and new partnerships and on the clinical progress of its proprietary ATAC pipeline. Cash at end-9M17 was €4.5m; the company has an additional funding commitment of €5.6m, sufficient into Q218.

Heidelberg Pharma

Termination of coverage

Update | Pharmaceutical & healthcare | 05 Jan 2016

Edison Investment Research is terminating coverage on Wilex (WL6). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Heidelberg Pharma

Seeking new partners

QuickView | Pharmaceutical & healthcare | 09 Nov 2015

Wilex's subsidiary, Heidelberg Pharma, is developing antibody targeted amanitin conjugates (ATACs), which are differentiated from first-in-class and developing antibody drug conjugates by potential efficacy against dormant and proliferating tumours. The investment case rests on the company's ability to form new partnerships for the ATAC pipeline and on clinical partnering progress for renal cancer programmes.

Heidelberg Pharma

Seeking partners for novel ADC technology

Update | Pharmaceutical & healthcare | 05 Nov 2015

Wilex's subsidiary, Heidelberg Pharma, is developing antibody-targeted amanitin conjugates (ATACs), which are differentiated from first-in-class, and developing antibody drug conjugates by potential efficacy against dormant and proliferating tumours. The investment case rests on the new partnerships for the ATAC pipeline and on clinical partnering progress for renal cancer programmes. Our DCF valuation is €41m.

Heidelberg Pharma

ATACs: A step closer to the clinic

Update | Pharmaceutical & healthcare | 05 May 2015

Wilex's subsidiary is developing Antibody Targeted Amanitin Conjugates (ATACs), which are differentiated from first-in-class and developing antibody drug conjugates by potential efficacy against dormant and proliferating tumours. Visibility on clinical timelines is improving, validated by the extended Roche collaboration, supported by milestones up to €52m for one ATAC target. We have raised our valuation from €46m to €57m.

Activa Resources

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Sector Commentary: | *Multiple Sectors | 11 Nov 2014

-

Heidelberg Pharma

Redefined and refined

Update | Pharmaceutical & healthcare | 24 Jul 2014

Wilex has fulfilled its target of establishing global licence deals for Mesupron, opening up the opportunity to confirm its potential across a range of oncology indications. The new, leaner Wilex is focusing on its antibody drug conjugate ADC technology and targets additional alliances along the lines of its existing tie-up with Roche. It also seeks partners for the clear cell renal cancer programme. Our valuation is €46m, which could increase to €116m if Wilex can out-license Rencarex and Redectane.

Simavita

Edison healthcare quarterly: It’s getting personal

Sector Commentary: | Pharmaceutical & healthcare | 30 Jun 2014

-

TESARO

Edison healthcare quarterly: A boost for allergy immunotherapy

Sector Commentary: | Pharmaceutical & healthcare | 05 Mar 2014

-

Heidelberg Pharma

Breathing space

Update | Pharmaceutical & healthcare | 05 Feb 2014

Wilex is implementing significant cost reductions to extend its cash reach. Its focus has shifted onto its early-stage R&D pipeline, notably the potential of its innovative ADC technology and the preclinical service business. While partnering efforts for the late-stage pipeline have so far not been fruitful, Wilex now has greater flexibility to negotiate for the deals it seeks. Our valuation and financial forecasts are under review pending further guidance from the company.